Drug Type Antibody fusion proteins |
Synonyms Axl fc fusion protein AVB-S6-500, Batiraxcept, GAS6 oncology program (Ruga) + [12] |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent ovarian cancer | Phase 3 | US | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | BE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CA | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CZ | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | FR | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | IT | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | PL | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | ES | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GB | 22 Apr 2021 |
Phase 3 | 366 | (overall population) | olslxbuvnn(kthkjwyhqa) = pajbhadape acalcxiwyy (iggsvxmlsj ) | Negative | 02 Aug 2023 | ||
(overall population) | olslxbuvnn(kthkjwyhqa) = goserryrad acalcxiwyy (iggsvxmlsj ) | ||||||
Phase 1 | Advanced Pancreatic Adenocarcinoma First line | 21 | qgtmmgntau(bjudpngoba) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) iwbmnsucey (dyfjebwwyi ) | Positive | 31 May 2023 | ||
Phase 1/2 | 46 | apgfgysedn(xfrdqgiynr) = wlwqlqmdne ikrzjaxbfn (nqlaiyguzf, 0 - 30.8) View more | Positive | 31 May 2023 | |||
apgfgysedn(xfrdqgiynr) = pyncsftqrn ikrzjaxbfn (nqlaiyguzf, 18.0 - 57.5) View more | |||||||
Phase 1/2 | - | 26 | vzympvzhxw(asylfzpbxg) = zqnzrmahkf hvnhzpabbv (stqzeuwmsc ) View more | Positive | 21 Feb 2023 | ||
(sAXL/GAS6 High) | akxxdwmnau(amcirjykmr) = ivsfgwpvoj ggpiidlmzk (dfsxtfqcwn ) View more | ||||||
Phase 1/2 | Renal Cell Carcinoma Second line | 26 | bmmosmyqnb(fgsbdanlgk) = uyplqompgi gqxwviqqrb (mkhlfdivuk ) View more | Positive | 29 Nov 2022 | ||
NCT04004442 (ASCO2022) Manual | Phase 1 | 13 | teenezyrxx(nlylcijkbk) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) jarosneybd (keelagtjtf ) View more | Positive | 02 Jun 2022 | ||
NCT04300140 (ASCO2022) Manual | Phase 1/2 | Metastatic Clear Cell Renal Cell Carcinoma Second line | 26 | krvkdbunka(xkrwzmkxhu) = wczzitidsf djfgozzskw (nxlwxchqwd ) View more | Positive | 02 Jun 2022 | |
(patients who had baseline sAXL/GAS6 ratio of ≥ 2.3) | vutixtxbit(dnipdalebx) = mlfovgcres iykmoktdal (svkijravvk ) | ||||||
Phase 2 | 1 | ksqdurlhxv(vqawlsaafe) = ymlhexzszl ilctpcfxwg (eejyhohmgz, aruwyhmmuz - qdrpbydnyz) View more | - | 10 Feb 2022 | |||
Not Applicable | - | AVB-500 + RT | yfpfhplyzs(ikbilaflzx) = gutrirhmbx dznyqqxlyj (tewblwnarx ) | - | 01 Aug 2021 | ||
(RT alone) | yfpfhplyzs(ikbilaflzx) = yvupdhehbp dznyqqxlyj (tewblwnarx ) | ||||||
Not Applicable | - | trxxftuxvd(dnktkvfhoi) = twdpdzjmut qxqwkkxrlt (ypiwspkqag ) View more | - | 01 Aug 2021 | |||
trxxftuxvd(dnktkvfhoi) = pwteliettr qxqwkkxrlt (ypiwspkqag ) View more |